<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_ColumbiaNYC_Composite_Part skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:ColumbiaNYC/Composite Part</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="container"><DIV class="navbar-header"><BUTTON type="button" class="navbar-toggle" data-toggle="collapse" data-target="#navbar-id" aria-expanded="false"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON></DIV><DIV class="collapse navbar-collapse" data-hover="dropdown" data-animations="pulse" id="navbar-id"><UL class="nav navbar-nav"><LI id="navbar-brand"><A href="https://2017.igem.org/Team:ColumbiaNYC" style="text-decoration: none; background-color:transparent !important; color:#fff;">
										COLUMBIA UNIVERSITY
									</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Team">TEAM</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Team">ABOUT US</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Attributions">ATTRIBUTIONS</A></LI></UL><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Description">PROJECT</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Description">DESCRIPTION</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Design">PROOF OF CONCEPT</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Results">RESULTS</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/HP/Silver">SAFETY</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/InterLab">INTERLAB</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Applied_Design">APPLIED DESIGN</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Improve">FUTURE WORK</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Part_Collection">PARTS</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Basic_Part">BASIC PARTS</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Composite_Part">COMPOSITE PARTS</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Part_Collection">PARTS COLLECTION</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Model">MODELLING</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Notebook">NOTEBOOK</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Brainstorm">BRAINSTORM</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Notebook">LAB NOTEBOOK</A></LI><LI class="dropdown"><A class="dropdown-toggle" href="https://2017.igem.org/Team:ColumbiaNYC/Engagement">HUMAN PRACTICES</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/HP/Gold_Integrated">HUMAN PRACTICES</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Engagement">ENGAGEMENT</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Entrepreneurship">ENTREPRENEURSHIP</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Collaborations">COLLABORATIONS</A></LI><LI><A href="https://2017.igem.org/Team:ColumbiaNYC/Medals">MEDAL CRITERION</A></LI></DIV></DIV><DIV class="jumbotron"><DIV class="container"><H1>Composite Parts</H1></DIV></DIV><DIV class="container"><DIV class="row"><H1>Best Composite Part</H1><DIV class="col-lg-12"><DIV class="col-lg-6 col-md-12"><H2>BBa_K2412001</H2><A href="http://parts.igem.org/Part:BBa_K2412001">iGEM BioBrick Link</A><P>This part utilizes a basic part (BBa_K2412000) which is an shRNA sequence that is incorporated into a T7 circuit
            in order to knock down eGFP.</P></DIV><DIV class="col-lg-6 col-md-12"><P>We produced the shRNA in vitro using the New England Biolabs T7 expression kit to use in the lipofectamine assay.
            After the in vitro shRNA is successful, we reran the lipofectamine assay with shRNA that was produced in vivo
            using IPTG induction. The shRNA produced in vivo was isolated using the miRNeasy kit. We extracted a significant
            quantity of shRNA using both in vitro expression and in vivo expression. In in vitro expression, the concentration
            of shRNA was about 2230 ng/uL. In in vivo expression, concentrations ranged from 850 ng/uL to 1070 ng/uL. The
            lipofectamine assay would test whether the shRNA successfully knocks down the eGFP in mammalian cells. In this
            assay, the shRNA would be introduced into liposomes, and then the liposomes would be introduced into the mammalian
            cell line. The liposomes would fuse with the cell membrane of the mammalian cells and then the shRNA would enter
            the cells. Upon entry, the shRNA would knock down the expression of eGFP.
          </P><P>The effectiveness of the knockdown of eGFP from the shRNA is measured using a flow cytometer. The flow cytometer
            measures the GFP florescence in every cell and gives a statistical distribution of the florescence. The results
            from the synthesized shRNA is compared to a negative control, where none of the shRNA is introduced to the mammalian
            cells during the lipofectamine assay. The results will also be compared to a positive control, where we used
            siRNA designed and proven to knock down eGFP from Thermo Fisher. We analyze the decrease in florescence to determine
            the effectiveness of the shRNA-mediated knockdown of GFP.
          </P></DIV></DIV><DIV class="col-lg-12"><DIV class="col-lg-6 col-md-12"><P>This graph illustrates the data collected from the flow cytometer after our lipofectamine assay.
          </P><P style="font-size:12px">Figure 1: The x-axis shows the negative control (PBS), the positive controls (siRNA), and the experimental shRNA
            designed to inhibit eGFP (shRNA). The y-axis shows the percentage of mammalian cells that were fluorescing eGFP
            (defined as eGFP positive). The error bars are 2 standard error, or a 95% confidence interval. As can be seen,
            the confidence intervals for the negative control and the experimental shRNA do not overlap, which shows that
            this difference is statistically significant. This indicates that our shRNA successfully knocks down eGFP expression
            in HeLa cells.
          </P></DIV></DIV><H1>Second Composite Part</H1><DIV class="col-lg-12"><DIV class="col-lg-6 col-md-12"><H2>BBa_K2412003</H2><A href="http://parts.igem.org/Part:BBa_K2412003">iGEM BioBrick Link</A><P>This part utilizes a basic part (BBa_K2412002) which is an shRNA sequence that is incorporated into a T7 circuit
              in order to knock down EGFR.</P></DIV></DIV></DIV></DIV><DIV class="footer-right"><P> Email: cuigem2017team@googlegroups.com </P></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>